SWP
VTGN icon

Stratos Wealth Partners’s VistaGen Therapeutics VTGN Stock Holding History

Stratos Wealth Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42
Closed -$2K – 2473
2018
Q3 		$2K Buy
+42
New +$1.7K ﹤0.01% 2746
2018
Q2 		– Sell
-42
Closed -$1K – 2561
2018
Q1 		$1K Buy
+42
New +$1.56K ﹤0.01% 3045

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Stratos Wealth Partners's VTGN Position: Q4 2018 in Review

Stratos Wealth Partners sold out of VistaGen Therapeutics (VTGN) in Q4 2018, closing a stake of 42 shares — an estimated $2K sold.

Stratos Wealth Partners first reported a position in VTGN in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q3 2018. 21 funds tracked by Wall St. Rank hold VTGN as of Q4 2018.

  • Stratos Wealth Partners reported no remaining VistaGen Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 42 VistaGen Therapeutics shares in Q4 2018, an estimated $2K.
  • Stratos Wealth Partners first reported a position in VistaGen Therapeutics in Q1 2018 and held it in 2 quarters.
  • Stratos Wealth Partners's VistaGen Therapeutics position peaked at $2K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.